French drone maker Parrot posts rise in first-quarter revenue
The company, which makes lightweight drones and mapping software, reported first-quarter revenue of 18.4 million euros ($20.6 million), 17% higher from the same period a year earlier.
The sales increase was supported by a strong performance at its professional microdrones division, which generates 57% of the group revenue.
Sales in this segment, which grew 13% from the same period a year ago, were buoyed by strong demand in several international markets, including North America, the UK and Japan.
Parrot exited the consumer drone market in 2021 and since then designs and sells small drones and mapping software for corporate and government clients.
Its client base includes the British Royal Airforce, the U.S. Army, the French Armed Forces, the Belgian Defence Force, the Counter Terrorist Operations Center of the Royal Thai Armed Forces, and the Japanese Ground Self-Defence Force.
Along its full-year 2024 results in March, the group said it was planning on capitalising on increasing defence budgets in its key markets, echoing remarks by French underwater drones maker Exail and supplier of night-vision systems to NATO, Exosens.
($1 = 0.8937 euros)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Senior analyst says Coinbase is a clear winner over Circle
Senior analyst says Coinbase is a clear winner over Circle originally appeared on TheStreet. Coinbase is becoming a better investment than Circle after the stablecoin issuer's highly anticipated but contentious public debut, said Mizuho Securities senior analyst Dan Dolev. Mizuho Financial Group, Inc. is one of Japan's biggest "megabanks" and is also a Global Systemically Important Bank. It has companies that provide retail and corporate banking, investment banking, asset management, and other financial services across the world. Dolev told CNBC that Circle's post-IPO value seemed too high since investors are assuming a 40% compound annual growth rate that "is not moving" in the real data. He said, "You have these really high ambitions, but the reality is it's not materializing." Dolev said that the recent change in U.S. government policy has made it easier for stablecoins to be used, but that Circle's USDC has not been adopted as much as investors had stablecoin is primarily being used to settle crypto and Bitcoin transactions on Coinbase — a dynamic that significantly benefits Coinbase's bottom line more than Circle's. When asked if he prefers Coinbase more than Circle, he replied, "Yes, 100%". According to Dolev, Coinbase has the upper hand. "They're getting 100% of all the coins that are on their platform and 50% of the coins that are not on their platform. So they're basically getting paid either way," explained Dolev. The analysts showed that the market as a whole is uncertain whether Circle can expand beyond specialist use cases into mainstream consumer use. The IPO shows that there is a lot of interest in crypto-related stocks, but Dolev told investors to stick with 'quality names" like Robinhood and Coinbase, which he thinks are better positioned. At press time, Circle (CRCL) was trading at $153, down by 6.17% in the last 24 hours. Meanwhile, Coinbase (COIN) is trading at $324.65, up 0.63% in the same time. Senior analyst says Coinbase is a clear winner over Circle first appeared on TheStreet on Aug 13, 2025 This story was originally reported by TheStreet on Aug 13, 2025, where it first appeared. Sign in to access your portfolio
Yahoo
18 minutes ago
- Yahoo
Optiva Inc. Reports Second Quarter 2025 Financial Results
All amounts are stated in United States dollars unless otherwise indicated Revenue of $10.3 million Total Contract Value ('TCV')(1) bookings of $26.6 million Gross margin of 49% Adjusted EBITDA(1) loss of $1.6 million EPS loss of $ 0.71 $12.9 million of cash TORONTO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Optiva Inc. ('Optiva' or 'the Company') (TSX:OPT), a leader in powering the telecom industry with cloud-native billing, charging and revenue management software on private and public clouds, today released its second quarter financial results for the three-month period ended June 30, 2025. Demonstrating continued bookings growth, during the second quarter, Optiva was selected by two new customers, a Tier 1 European mobile virtual network operator (MVNO) and a Tier 1 European telecom. This brings the total to 13 new customers in two years, a clear sign of confidence in the Company's roadmap and portfolio. Additionally, a key current customer has signed an extended multi-year BSS platform support agreement. Further, the Company was chosen as a finalist for the Most Innovative Telco AI/ML Product or Solution for the upcoming Leading Lights Awards by Light Reading. Update Regarding Optiva's Matured Secured Notes and Strategic TransactionAs announced on July 18, 2025, the company has entered into a 45-day support agreement with 85% of noteholders, allowing the Company to negotiate a transaction with a strategic third party. The negotiations have progressed, and while there can be no assurances that a successful transaction will be completed, it is expected that a binding agreement will be reached prior to the end of the 45-day forbearance period. Optiva has continued to operate in the ordinary course, upholding its commitments to customers, employees and suppliers since the maturity of the Notes, and with approximately $12 million cash on hand, it has the liquid resources to meet its working capital commitments for the foreseeable future. "We are deeply grateful to our customers for their continued trust as we finalize our future ownership structure. This transition will lead to an even stronger, more dynamic Optiva, greatly benefiting them. I also extend my sincere gratitude to the entire Optiva team. Their world-class capabilities and powerful innovations are evident in our strong momentum, reflected in new customer wins and product adoption,' said Robert Stabile, Chief Executive Officer of Optiva. For more information about Optiva, please visit: Business Highlights TCV of Q2 bookings totaled $26.6 million. For the trailing twelve months, TCV of bookings totaled $64.3 million. A Tier 1 European MVNO selected Optiva to modernize its business support systems (BSS). Optiva will deploy its AI-enabled, end-to-end stack, empowering the MVNO to achieve next-level agility, flexibility and scalability. Optiva BSS Platform and its AI-driven analytics tools will be deployed across multiple countries and markets. The modernization will further position the MVNO at the forefront of the industry, aligning with its broader digital transformation strategy to continue leading in the MVNx, mobile-first, experience-driven era. A Tier 1 European telecom chose Optiva to power its next-generation mobile virtual network enabler (MVNE) platform. With Optiva's modular, full end-to-end, AI-enabled BSS stack at its core, the operator will offer an enhanced and agile solution to MVNOs and other wholesale customers, including fixed wireless access (FWA) and fiber-to-the-home (FTTH) providers. Optiva BSS Platform will offer modularity and choice to the operator's customers, allowing them to select and customize capabilities tailored to their specific business needs, driving differentiation, innovation and new revenue. Digitel, a leading mobile network operator in Venezuela with more than 7.2 million subscribers and an Optiva customer since 2014, renewed its BSS platform support agreement for an additional three years. Optiva was named a finalist for Most Innovative Telco AI/ML Product or Solution for the Leading Lights 2025 Awards by Light Reading. The nomination recognizes how Optiva solutions apply AI and machine learning to support the changing needs of communications network operators. Second Quarter 2025 Financial Results Highlights: Q2 Fiscal 2025 Highlights Three Months Ended Six Months Ended ($ US Millions, except per share information) June 30, June 30, (Unaudited) 2025 2024 2025 2024 Revenue 10.3 11.4 21.8 23.1 Net Income (Loss) (4.4 ) (5.6 ) (6.8 ) (11.6 ) Earnings (Loss) Per Share ($0.71 ) ($0.90 ) ($1.09 ) ($1.88 ) Adjusted EBITDA(1) (1.6 ) (1.7 ) (1.2 ) (4.0 ) Cash from (used in) operating activities 4.9 5.2 1.9 1.8 Total cash, including restricted cash 12.9 17.1 12.9 17.1 Revenue for Q2'25 was $10.3 million. On a year-over-year basis, the change by revenue type included a $1.0 million decrease in support and subscription revenue, $0.1 million decrease in software and services revenue and no change in third party software and hardware revenue. The decrease in support and subscription in the period mainly relates to the earlier than expected discontinuation of support by migrating customers. Gross margin for Q2'25 was 49% compared to 56% during the same period in 2024. The decrease in gross margin is primarily attributable to lower revenue from high margin support and subscription revenue and higher amount of customizations with lower margins ordered by customers that required fulfillment, compared to the previous period. We expect our gross margins may fluctuate as our cloud-native model and product capabilities are adopted by new and existing customers in the public or private cloud in future periods. Adjusted Earnings before interest, taxes, depreciation and amortization ("EBITDA")1 for Q2 was a loss of $1.6 million as compared to loss of $1.7 million during the same period in 2024. Net loss for Q2 was $4.4 million compared to a net loss of $5.6 million during the same period in 2024. The net loss for the three months ended June 30, 2025, was lower mainly due to the lower operations expenses incurred during the period compared to last year. The company's lower operating expenses reflect ongoing efforts to optimize resources in support of our product roadmap, customer service, expanding our customer base, and administrative needs. The Company ended the second quarter with a cash balance of $12.9 million (including restricted cash.) (1) EBITDA, Adjusted EBITDA, TCV and adjusted EPS are non-IFRS measures. These measures are defined in the "Non-IFRS Measures" section of this news release. Non-IFRS Measures 'EBITDA" and "Adjusted EBITDA" are not financial measures calculated and presented in accordance with International Financial Reporting Standards (IFRS) and should not be considered in isolation or as a substitute to net income (loss), operating income or any other financial measures of performance calculated and presented in accordance with IFRS, or as an alternative to cash flow from operating activities as a measure of liquidity. The Company defines EBITDA as net income (loss) excluding amounts for depreciation and amortization, other income, finance costs, finance income, income tax expense (recovery), foreign exchange gain (loss) and share-based compensation. The Company defines "Adjusted EBITDA" as EBITDA (as defined above), excluding restructuring costs, one-time provision amounts and other one-time unusual items. The Company believes that Adjusted EBITDA is a metric that investors may find useful in understanding the Company's financial position. The following table provides a reconciliation of Net Income to EBITDA and Adjusted EBITDA (in thousands of U.S. dollars). Three months ended, June 30, Six months ended, June 30, 2025 2024 2025 2024 Net loss for the period $ (4,415 ) $ (5,601 ) $ (6,754 ) $ (11,633 ) Add back / (subtract): Depreciation of computer equipment 75 153 188 332 Finance income (68 ) (132 ) (156 ) (325 ) Finance costs 2,991 2,845 5,897 5,674 Income tax expense (recovery) 295 343 496 582 Foreign exchange loss (gain) (500 ) 86 (584 ) 248 Share-based compensation (21 ) 593 (270 ) 1,100 EBITDA and Adjusted EBITDA $ (1,643 ) $ (1,713 ) $ (1,183 ) $ (4,022 ) TCV is the Total Contract Value of all bookings closed in the period. About Optiva Optiva Inc. is a leading provider of mission-critical, cloud-native, agentic AI-powered revenue management software for the telecommunications industry. Its products are delivered globally on the private and public cloud. The Company's solutions help service providers maximize digital, 5G, IoT and emerging market opportunities to achieve business success. Established in 1999, Optiva Inc. is listed on the Toronto Stock Exchange (TSX:OPT). For more information, visit Caution Concerning Forward-Looking Statement Certain statements in this document may constitute "forward-looking" statements that involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. When used in this document, such statements use such words as "may," "will," "expect," "continue," "believe," "plan," "intend," "would," "could," "should," "anticipate" and other similar terminology. Forward-looking statements in this document include statements regarding the Company's "qualified pipeline", the TCV of the qualified pipeline and the Company's expectations regarding future revenues. We draw your attention to the "Risks and Uncertainties" section of the Company's management's discussion and analysis for the quarter ended June 30,2025, and to note 1 of our consolidated financial statements which indicate the existence of material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern. The Company had a working capital deficit (current assets less current liabilities) of $101.9 million as at June 30, 2025 (December 31, 2024 – working capital deficit of $94.8 million), reflecting inclusion of the 9.75% secured PIK toggle debentures due July 20, 2025 (the 'Debentures') as a current liability. The Debentures in the amount of $108.6 million as of June 30, 2025, had a scheduled maturity date of July 20, 2025. Based on the cash balance as of June 30, 2025 and the cash flows from operations to the Debentures scheduled maturity date, the Company had insufficient cash to meet its obligations upon maturity of the Debentures. The Company's board of directors has formed a special committee of independent directors that are actively engaged with strategic third parties, including key holders of the Secured Notes, for purposes of evaluating strategic alternatives, including a potential transaction, to optimize outcomes for the business, our people, and our customers. On July 18, the Company entered into a support agreement (the 'Support Agreement') with the holders of approximately 85% of the outstanding principal amount of the Debentures. The Support Agreement provides the Company with a 45-day grace period (the "Grace Period") to allow the Special Committee to conclude negotiations with the Debenture holders and prospective merger counterparties regarding a potential transaction. During the Grace Period, Debenture holders who are parties to the Support Agreement have agreed to forbear from exercising any of their rights or remedies in connection with any payment default occurring on the scheduled maturity of the Debentures on July 20, 2025. This Grace Period may be extended at the election of the Debenture holders. The Company's ability to continue its operations is dependent upon its ability to refinance the debentures or implement other financial alternatives, including other sources of financing through debt or equity, however there is no assurance that this will be successful. These factors indicate the existence of a material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern. These statements are forward-looking as they are based on our current expectations, as at August 13, 2025, about our business and the markets we operate in and on various estimates and assumptions. Our actual results could materially differ from our expectations if known or unknown risks affect our business or if our estimates or assumptions turn out to be inaccurate. As a result, there is no assurance that any forward-looking statements will materialize. Risks that could cause our results to differ materially from our current expectations include the risk that the Company will not secure contracts with customers that are included in its qualified pipeline, the risk that existing customers may decrease their spend with the Company and other risks that are discussed in the Company's most recent Annual Information Form, available on SEDAR at and Optiva's website at Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Optiva does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. For additional information, please contact: Media Contact: Misann Ellmakermedia@ Investor Relations: investors-relations@ Inc. Condensed Consolidated Interim Statements of Financial Position (Expressed in thousands of U.S. dollars) (Unaudited) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 11,446 $ 10,217 Trade accounts and other receivables 5,111 7,229 Unbilled revenue 10,467 9,292 Prepaid expenses 1,809 1,994 Income taxes receivable 355 346 Other assets 1,189 1,034 Total current assets 30,377 30,112 Restricted cash 1,438 843 Computer Equipment 431 571 Deferred income taxes 425 475 Other assets 3,111 2,712 Long-term unbilled revenue 345 384 Pension and other long-term employment benefit plans 1,906 2,773 Goodwill 32,271 32,271 Total assets $ 70,304 $ 70,141 Liabilities and Shareholders' Equity (Deficit) Current liabilities: Trade payables $ 1,805 $ 1,940 Accrued liabilities 13,704 14,229 Income taxes payable 3,030 3,367 Deferred revenue 5,246 2,688 Debentures 108,492 102,701 Total current liabilities 132,277 124,925 Deferred revenue 136 64 Other liabilities 1,376 1,768 Deferred income taxes 85 126 Total liabilities 133,874 126,883 Shareholders' equity (deficit): Share capital 270,760 270,746 Contributed surplus 15,221 15,309 Deficit (355,316 ) (348,562 ) Accumulated other comprehensive income 5,765 5,765 Total shareholders' equity (deficit) (63,570 ) (56,742 ) Total liabilities and shareholders' equity (deficit) $ 70,304 $ 70,141 OPTIVA Inc. Condensed Consolidated Interim Statements of Comprehensive Income (loss) (Expressed in thousands of U.S. dollars, except per share and share amounts) (Unaudited) Three months ended, June 30 Six months ended, June 30, 2024 2024 2025 2024 Revenue: Support and subscription $ 6,415 $ 7,432 $ 13,915 $ 14,762 Software licenses, services and other 3,837 3,961 7,929 8,335 10,252 11,393 21,844 23,097 Cost of revenue 5,209 5,028 9,336 9,916 Gross profit 5,043 6,365 12,508 13,181 Operating expenses: Sales and marketing 2,148 2,508 4,072 5,264 General and administrative 1,851 2,626 3,526 5,643 Research and development 2,741 3,690 6,012 7,728 6,740 8,824 13,610 18,635 Income (loss) from operations (1,697 ) (2,459 ) (1,102 ) (5,454 ) Foreign exchange gain (loss) 500 (86 ) 584 (248 ) Finance income 68 132 157 325 Finance costs (2,991 ) (2,845 ) (5,897 ) (5,674 ) Loss before income taxes (4,120 ) (5,258 ) (6,258 ) (11,051 ) Income tax expense (recovery): Current 262 385 488 679 Deferred 33 (42 ) 8 (97 ) 295 343 496 582 Total net loss and comprehensive loss $ (4,415 ) $ (5,601 ) $ (6,754 ) $ (11,633 ) Net loss per common share Basic $ (0.71 ) $ (0.90 ) $ (1.09 ) $ (1.88 ) Diluted (0.71 ) (0.90 ) (1.09 ) (1.88 ) Weighted average number of common shares (thousands): Basic 6,222 6,212 6,218 6,196 Diluted 6,222 6,212 6,218 6,196 OPTIVA Inc. Condensed Consolidated Interim Statements of Cash Flows (Expressed in thousands of U.S. dollars) (Unaudited) Three months ended, June 30 Six months ended June 30, 2025 2024 2025 2024 Cash provided by (used in): Operating activities: Net loss for the year $ (4,415 ) $ (5,601 ) $ (6,754 ) $ (11,633 ) Adjustments for: Depreciation of property and equipment 75 153 188 332 Finance income (68 ) (132 ) (156 ) (325 ) Finance costs 2,991 2,845 5,897 5,674 Pensions 1,801 (777 ) 1,354 (864 ) Income tax expense 295 343 496 582 Unrealized foreign exchange (gain) / loss (264 ) (60 ) (429 ) (374 ) Share-based compensation (21 ) 593 (270 ) 1,100 Change in non-cash operating working capital 3,457 5,651 2,483 5,351 3,851 3,015 2,809 (157 ) Interest paid (2 ) (6 ) (2 ) (6 ) Interest received 51 114 139 286 Income taxes received (paid) 1,031 2,090 (1,084 ) 1,654 4,931 5,213 1,862 1,777 Financing activities: Payment of interest on debentures - - - (5,086 ) - - - (5,086 ) Investing activities: Purchase of property and equipment (58 ) (181 ) (58 ) (381 ) Decrease (increase) in restricted cash 38 (1 ) (594 ) 8 (20 ) (182 ) (652 ) (373 ) Effect of foreign exchange rate changes on cash and cash equivalents (12 ) 62 19 376 Decrease in cash and cash equivalents 4,899 5,093 1,229 (3,306 ) Cash and cash equivalents, beginning of period 6,547 11,243 10,217 19,642 Cash and cash equivalents, end of period $ 11,446 $ 16,336 $ 11,446 $ 16,336 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
Cybin continues to make significant progress on its journey to bring breakthrough therapies to patients by delivering on the following key milestones - Received European and United Kingdom Medical and Healthcare Products Regulatory Agency ("MHRA") approval for EMBRACE, the Company's second pivotal study evaluating CYB003 for the adjunctive treatment of Major Depressive Disorder ("MDD") on schedule - - EMBRACE study to enroll 330 participants at approximately 60 clinical sites across the United States, United Kingdom, Europe, and Australia1 - - Completion of patient enrollment in CYB004 Phase 2 study in General Anxiety Disorder expected in August 20251 - - Recent financing agreement of US$50 million principal amount of convertible debentures will advance clinical pipeline programs - - Cash totaled US$118.7 million as of June 30, 2025 - This news release constitutes a "designated news release" for the purposes of Cybin's prospectus supplement dated February 10, 2025, to its short form base shelf prospectus dated August 17, 2023, as amended December 22, 2023, April 8, 2024, and January 6, 2025. TORONTO, August 13, 2025--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its first quarter ended June 30, 2025, and is pleased to provide an update on key business milestones. "With our recently announced funding agreement in place, we are well positioned to continue advancing our lead clinical programs, CYB003 and CYB004, through multiple inflection points," said Doug Drysdale, Chief Executive Officer of Cybin. "Gaining European CTA approval and MHRA approval to commence EMBRACE in the UK has enabled us to expand our multinational Phase 3 PARADIGM program evaluating CYB003 for the potential adjunctive treatment of major depressive disorder. PARADIGM is a significantly larger program than the completed Phase 2 study, with anticipated combined enrollment of approximately 550 participants. Our Phase 3 studies will evaluate the potential clinical benefits of CYB003 in patients living with moderate to severe MDD, and whose symptoms are uncontrolled with existing antidepressant treatment. Our Phase 2 study evaluating CYB004 in generalized anxiety disorder is expected to complete patient enrollment this month." "Cybin is in a strong position to advance our programs and continue our work to deliver innovative therapies to address some of the most challenging mental health disorders we face today and is helping to build momentum across the sector - both from a clinical and regulatory perspective," concluded Drysdale. Recent Business and Pipeline Highlights: Received European approval and MHRA approval for EMBRACE, the second Phase 3 study within the PARADIGM program evaluating CYB003 for the adjunctive treatment of MDD, on schedule. The Company has received CTA approval from the Irish Medicines Board for the EMBRACE study in Ireland, Poland, and Greece, as well as approval from the MHRA. EMBRACE is a 12-week, randomized, double-blind, placebo-controlled study in 330 participants with moderate to severe MDD (MADRS≥24) who are on a stable dose of antidepressant medication but with inadequate response. EMBRACE will evaluate two doses of CYB003 (8 mg, 16 mg) three weeks apart, compared to an inactive placebo. The primary endpoint is change in depressive symptoms as measured by the change in MADRS from baseline six weeks after the first dose. Making strong progress on CYB003 development through the APPROACH and EXTEND studies. Dosing is currently ongoing in the first pivotal study, APPROACH, which is expected to enroll 220 patients across 45 U.S. clinical sites. We are pleased to report that patient rollovers continue into EXTEND, the long-term extension study. Clinical Program Summary CYB003: Deuterated psilocin program Phase 3 PARADIGM program is underway, with topline data from first pivotal study, APPROACH, expected in 20261. CYB003 program accomplishments: Received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of MDD. A completed Phase 2 study of CYB003 in MDD demonstrated durability of effect at 12 months: 100% of participants receiving two doses of 16 mg were responders. 71% of participants receiving two doses of 16 mg were in remission. Mean change from baseline in MADRS was approximately -23 points after two 16 mg doses. CYB004: Deuterated dimethyltryptamine program The Phase 2 CYB004 study is a randomized, double-blind study evaluating the safety and efficacy of CYB004 in participants with generalized anxiety disorder, with concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed. Patient enrollment is expected to be completed this month1. Change in Presentation Currency Effective April 1, 2025, the Company changed its presentation currency from the Canadian dollar to the United States dollar ("USD"). The change in presentation currency was made to better reflect the Company's operations, align with the currency in which the majority of cash-based expenses are denominated, and improve comparability of its financial results with other publicly traded businesses in the industry. As a result, all amounts presented in this press release are in USD unless otherwise stated. First-Quarter Financial Highlights Cash totaled $118.7 million as of June 30, 2025. Net loss was $24.6 million for the quarter ended June 30, 2025, compared to a net loss of $10.8 million in the same period last year. Cash-based operating expenses consisting of research, general, and administrative costs totaled $23.9 million for the quarter ended June 30, 2025, compared to $11.9 million, in the same period last year. Cash flows used in operating activities were $29.5 million for the quarter ended June 30, 2025, compared to $19.9 million in the same period last year. About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Note: There is no assurance that timelines will be met. Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See "Cautionary Notes and Forward-Looking Statements". Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, "forward-looking statements") and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "may", "should", "could", "potential", "possible", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the EMBRACE study to enroll 330 participants at approximately 60 clinical sites across the United States, United Kingdom, Europe, and Australia; the Company's expectation to enroll 220 participants at approximately 45 clinical sites across the United States for the APPROACH study; the Company's expectation to complete enrollment in CYB004 Phase 2 study in August 2025; the Company's expectation to receive topline data from APPROACH in 2026; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three months ended June 30, 2025, and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Neither Cboe Canada, nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein. View source version on Contacts Investor & Media Contact: Gabriel FahelChief Legal OfficerCybin Inc.1-866-292-4601irteam@ – or – media@
